ALK Positive, Inc. at ASCO (June 3-7, 2022)
"Going to ASCO was a great opportunity to network and represent the organization, help move ALK to the top, and let people know who we are. I feel it was a productive conference, and we look forward to continuing better relationships with everyone. As a patient-led organization, it is important for us that they see us and know that we are representing all ALK patients and their families to help with more ALK research." - Amanda Nerstad, vice president, ALK Positive, Inc.
Representatives from ALK Positive Inc. attended the annual ASCO meeting in Chicago, IL, in June this year. We hosted a Key Opinion Leader Breakfast attended by some of the top ALK experts including Dr. John Iafrate (Massachusetts General Hospital), Dr. Jessica Lin (Massachusetts General Hospital), Dr. Vincent Lam (Johns Hopkins University), Dr. Mark Awad (Dana Farber Cancer Institute), Dr. Tejas Patil (University of Colorado Cancer Center), Dr. Ben Creelan (Lee Moffit Cancer Center), Dr. Justin Gainor (Massachusetts General Hospital), and Dr. Angel Qin (University of Michigan Rogel Cancer Center).
All of these ALK experts discussed how we can advance ALK research and work together. It was a great opportunity to connect these experts, collaborate, and talk freely with them face to face. The session was moderated by Representatives from ALK Positive Inc's Research Acceleration Committee (Marc Muskavitch and others) as well as Dr. Scott Schell (CEO, ALK Positive, Inc.), Bill Westlake (Board President, ALK Positive, Inc.), and Amanda Nerstad (Vice President, ALK Positive, Inc.).
“As a patient-led organization, ALK Positive places extreme urgency behind developing new treatment options. ASCO allows us to collaborate with our top ALK doctors, researchers and future scientists to build a roadmap together to provide hope for those who ran out of standard of care options.”
- Bill Westlake, president, ALK Positive, Inc.
Representative of ALK Positive, Inc and ALK Experts at ASCO in Chicago.
"The ASCO annual meeting unites international oncology researchers and clinicians. This year's meeting felt especially vibrant with many new discoveries being reported, and gives us joy that we could meet and share ideas in person once again. ALK Positive is blessed to have brilliant Key Opinion Leaders who share our volunteers' passion to advance new therapies for patients with ALK-positive lung and other cancers worldwide.” - Scott Schell, CEO, ALK Positive, Inc.
Scott, Bill, and Amanda also attended private meetings with Genentech, Nuvalent, Daiichi Sankyo, Turning Point Therapeutics, Pfizer, Exact Sciences, Takeda, and other ALK-focused organizations and many different people to help further the mission of ALK positive.